Clinical Trial Update: HR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial update comparing HR070803 with oxaliplatin + 5-FU/LV versus GX as adjuvant therapy for pancreatic cancer; not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• GX
• HR070803
• Leucovorin (folinic acid)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Fudan University | Conditions: Pancreatic Cancer | Phase 3 | Status: NOT_YET_RECRUITING